BofA raised the firm’s price target on Krystal Biotech (KRYS) to $288 from $272 and keeps a Buy rating on the shares. Following updates from the phase 1 CORAL-1 study, the firm continues to like Krystal as one of its top picks for the year as it thinks both Vyjuvek and the pipeline could unlock “significant value,” the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech price target raised to $320 from $309 at Citi
- Krystal Biotech price target raised to $288 from $217 at Clear Street
- Krystal Biotech price target raised to $310 from $240 at H.C. Wainwright
- Early Proof-of-Concept and Platform Potential Drive Buy Rating on Krystal Biotech Despite Pending Lung Function Data
- Krystal Biotech advances KB407 with positive CF trial data